Below is a preliminary concept of the program. The symposium will showcase keynote talks and feature presentations exploring advances in radiometals with medical significance, highlighting their roles in chemical synthesis, radiopharmaceutical development, and clinical nuclear medicine from the following esteemed field experts:
TERACHEM 2026
Program
Dr. Ullie Köster,
Institut Laue-Langevin (ILL) & Université Grenoble Alpes
Dr. Julie L. Sutcliffe,
University of California Davis
Dr. Michael K. Schultz,
Perspective Therapeutics & University of Iowa
Dr. J. Peter Scott,
University of Michigan
In keeping with tradition, the program will be built primarily on the strength of submitted abstracts, which will be blindly reviewed by a panel of qualified experts. Topics include:
Radionuclide Production & Targetry
Chemistry of Technetium, Rhenium and Other Radiometals in Medicine
Chemistry of Other Radiometals & Ligand Design
Preclinical Development of Metal Based Radiopharmaceuticals & Radiopharmacology
Translational Radiotherapy and Radiotheragnostics
Radiopharmaceuticals Labeled with Technetium-99m and Other Radiometals
AI in Radiochemistry
